May 17, 2017, Cambridge, MA —Portal Instruments, a clinical stage medical device start-up company announced today the publication of study results in a peer-reviewed article in AAPS PharmSciTech, comparing pain scores of injections using Portal Instruments’ needle-free delivery system and a standard 27G needle. The results of the clinical trial involving 40 healthy volunteers demonstrated that the reported pain associated with an injection using the Portal system was significantly lower than that reported following a subcutaneous injection with a 27G needle. In addition, 60% of subjects stated that they preferred the Portal delivery experience when compared to that of a 27G needle.

“The publication of our study results in a peer-reviewed article marks an important milestone for the company,” said Patrick Anquetil, PhD, MBA, CEO of Portal Instruments. “These initial findings provide us with the confidence to move forward with additional research to advance drug delivery with a needle-free system that may potentially lead to improved patient satisfaction, improved adherence to treatment regimens, and a possible reduction of anxiety among patients requiring frequent or ongoing injections.”

“The Portal device has the potential to be a safe and less painful method of administering subcutaneous injections. The ultimate goal of the Portal technology is to provide a better overall drug delivery experience for patients, which we believe this study represents the first step towards achieving that goal,” said Nik Kojic, MD, PhD, VP of Clinical Development for Portal Instruments.

The Portal drug delivery technology is needle-free, fast and computer-controlled. It automatically adjusts the injection velocity up to one thousand times in the half-second it takes to completely deliver a 1 ml dose. The result is the precise administration of high viscosity biologic drugs through the skin, via a finely collimated jet. HIPAA-compliant, automatic collection and transfer of injection and health data sets a new standard of engagement between the care team and the patient. With a clear view of patient behavior, protocols can be better managed, research better informed and compliance improved.

An abstract of the article can be accessed here.


About Portal Instruments

Portal Instruments is a Series B funded medical device company focused on advanced drug delivery and backed by strategic and venture investors. Portal Instruments is developing and commercializing a highly innovative needle-free drug delivery platform technology to transform the administration of medicines and improve the patient experience for chronic diseases. Portal’s needle-free delivery technology is derived from research at MIT and enables the administration of high viscosity biologic drugs with less discomfort and without the anxiety of handling needles. Real time tracking and reporting sets a new standard for interactivity between the patient and care teams, monitoring adherence and potentially improving patient outcomes. Portal Instruments’ Quality Management System is ISO 13485 certified. For more information, please visit or follow @portalcambridge on Twitter.


About AAPS

The American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific organization of approximately 10,000 members employed in academia, industry, government, and other research institutes worldwide. Founded in 1986, AAPS advances the capacity of pharmaceutical scientists to develop products and therapies that improve global health.


Dr. Patrick Anquetil
Chief Executive Officer

Pages of the Portal Instruments website may contain links to third party websites that are not under the control of Portal Instruments. Portal Instruments is not responsible for the content of any such site and the inclusion of these links does not imply the endorsement of the content of the linked site by Portal Instruments.

Portal’s platform is in development and not available for sale or use.